Zacks Research Issues Optimistic Estimate for BMRN Earnings

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) - Analysts at Zacks Research raised their Q2 2025 earnings per share (EPS) estimates for shares of BioMarin Pharmaceutical in a report released on Wednesday, January 8th. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will post earnings per share of $0.69 for the quarter, up from their previous forecast of $0.68. The consensus estimate for BioMarin Pharmaceutical's current full-year earnings is $2.49 per share. Zacks Research also issued estimates for BioMarin Pharmaceutical's Q4 2026 earnings at $0.94 EPS and FY2026 earnings at $3.43 EPS.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last announced its quarterly earnings data on Tuesday, October 29th. The biotechnology company reported $0.55 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.78 by ($0.23). BioMarin Pharmaceutical had a net margin of 11.71% and a return on equity of 8.53%. The company had revenue of $746.00 million for the quarter, compared to the consensus estimate of $703.37 million. During the same period last year, the business posted $0.26 earnings per share. The firm's quarterly revenue was up 28.4% compared to the same quarter last year.

Other equities analysts have also recently issued research reports about the stock. Robert W. Baird decreased their price objective on shares of BioMarin Pharmaceutical from $72.00 to $65.00 and set a "neutral" rating on the stock in a research report on Wednesday, October 30th. Truist Financial lowered their price objective on shares of BioMarin Pharmaceutical from $118.00 to $90.00 and set a "buy" rating for the company in a report on Tuesday, September 17th. Barclays reduced their target price on BioMarin Pharmaceutical from $110.00 to $86.00 and set an "overweight" rating on the stock in a report on Friday, October 4th. Wedbush raised BioMarin Pharmaceutical to a "strong-buy" rating in a research note on Monday, November 4th. Finally, Wells Fargo & Company reduced their target price on shares of BioMarin Pharmaceutical from $115.00 to $90.00 and set an "overweight" rating on the stock in a research report on Tuesday, September 17th. Seven investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $94.20.

BioMarin Pharmaceutical Trading Down 1.2 %

Shares of NASDAQ:BMRN traded down $0.80 during trading on Monday, reaching $66.58. 174,846 shares of the company traded hands, compared to its average volume of 991,596. The company has a current ratio of 4.27, a quick ratio of 2.62 and a debt-to-equity ratio of 0.11. BioMarin Pharmaceutical has a 52-week low of $61.15 and a 52-week high of $94.85. The firm has a market capitalization of $12.69 billion, a price-to-earnings ratio of 39.87, a P/E/G ratio of 0.65 and a beta of 0.29. The business's fifty day moving average is $65.83 and its 200-day moving average is $74.96.

Insider Transactions at BioMarin Pharmaceutical

In other BioMarin Pharmaceutical news, EVP Charles Greg Guyer sold 5,278 shares of the stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $66.37, for a total value of $350,300.86. Following the sale, the executive vice president now directly owns 68,909 shares of the company's stock, valued at approximately $4,573,490.33. This represents a 7.11 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 1.85% of the company's stock.

Hedge Funds Weigh In On BioMarin Pharmaceutical

Large investors have recently bought and sold shares of the stock. BOKF NA purchased a new position in BioMarin Pharmaceutical during the second quarter worth about $31,000. nVerses Capital LLC acquired a new stake in shares of BioMarin Pharmaceutical during the third quarter valued at $28,000. TD Private Client Wealth LLC grew its holdings in shares of BioMarin Pharmaceutical by 57.4% during the third quarter. TD Private Client Wealth LLC now owns 510 shares of the biotechnology company's stock worth $36,000 after buying an additional 186 shares in the last quarter. Itau Unibanco Holding S.A. purchased a new stake in BioMarin Pharmaceutical in the 2nd quarter worth approximately $47,000. Finally, Meeder Asset Management Inc. increased its stake in BioMarin Pharmaceutical by 920.8% in the third quarter. Meeder Asset Management Inc. now owns 735 shares of the biotechnology company's stock valued at $52,000 after purchasing an additional 663 shares during the last quarter. Institutional investors and hedge funds own 98.71% of the company's stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.